Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Disparities in diabetes and hypertension care for individuals with serious mental illness.

Liu J, Brown J, Morton S, Potter DEB, Patton L, Patel M, Lewis R, Hudson Scholle S.

Am J Manag Care. 2017 May;23(5):304-308.

2.

The Current State of Behavioral Health Quality Measures: Where Are the Gaps?

Patel MM, Brown JD, Croake S, Lewis R, Liu J, Patton L, Potter DE, Scholle SH.

Psychiatr Serv. 2015 Aug 1;66(8):865-71. doi: 10.1176/appi.ps.201400589. Epub 2015 Jun 15. Review.

PMID:
26073415
3.

Ketamine: repurposing and redefining a multifaceted drug.

Potter DE, Choudhury M.

Drug Discov Today. 2014 Dec;19(12):1848-54. doi: 10.1016/j.drudis.2014.08.017. Epub 2014 Sep 16. Review.

PMID:
25224017
4.

Non-analgesic effects of opioids: neuroprotection in the retina.

Husain S, Abdul Y, Potter DE.

Curr Pharm Des. 2012;18(37):6101-8. Review.

PMID:
22747547
5.

Users of Medicaid home and community-based services are especially vulnerable to costly avoidable hospital admissions.

Konetzka RT, Karon SL, Potter DE.

Health Aff (Millwood). 2012 Jun;31(6):1167-75. doi: 10.1377/hlthaff.2011.0902.

PMID:
22665828
6.

Potentially Preventable Hospitalizations among Medicare-Medicaid Dual Eligibles, 2008: Statistical Brief #96.

Jiang HJ, Wier LM, Potter DEB, Burgess J.

Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-.
2010 Sep.

7.

Predictors of Success After a First Circumferential Pulmonary Vein Isolation For Atrial Fibrillation.

Potter T, Tavernier R, Devos D, Beeumen KV, Duytschaever M.

J Atr Fibrillation. 2009 Apr 1;1(6):161. doi: 10.4022/jafib.161. eCollection 2009 Apr-May.

8.

Opioid receptor-activation: retina protected from ischemic injury.

Husain S, Potter DE, Crosson CE.

Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3853-9. doi: 10.1167/iovs.08-2907. Epub 2009 Mar 25.

PMID:
19324855
9.

Staphylococcus aureus immunodominant surface antigen B is a cell-surface associated nucleic acid binding protein.

Mackey-Lawrence NM, Potter DE, Cerca N, Jefferson KK.

BMC Microbiol. 2009 Mar 26;9:61. doi: 10.1186/1471-2180-9-61.

10.

The opioidergic system: potential roles and therapeutic indications in the eye.

Husain S, Potter DE.

J Ocul Pharmacol Ther. 2008 Apr;24(2):117-40. doi: 10.1089/jop.2007.0112. Review. No abstract available.

PMID:
18355128
11.

Risk factors associated with the occurrence of fractures in U.S. nursing homes: resident and facility characteristics and prescription medications.

Spector W, Shaffer T, Potter DE, Correa-de-Araujo R, Rhona Limcangco M.

J Am Geriatr Soc. 2007 Mar;55(3):327-33.

PMID:
17341233
12.

Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties.

Dortch-Carnes J, Potter DE.

CNS Drug Rev. 2005 Summer;11(2):195-212. Review.

13.

Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents.

Lau DT, Kasper JD, Potter DE, Lyles A, Bennett RG.

Arch Intern Med. 2005 Jan 10;165(1):68-74.

PMID:
15642877
15.

Bremazocine increases C-type natriuretic peptide levels in aqueous humor and enhances outflow facility.

Potter DE, Russell KR, Manhiani M.

J Pharmacol Exp Ther. 2004 May;309(2):548-53. Epub 2004 Jan 23.

PMID:
14742737
17.

Changes in muscle proteins and spermidine content in response to unloading and clenbuterol treatment.

von Deutsch DA, Abukhalaf IK, Wineski LE, Silvestrov NA, Bayorh MA, Potter DE.

Can J Physiol Pharmacol. 2003 Jan;81(1):28-39.

PMID:
12665255
18.
19.
20.
21.

Ocular hypotension induced by electroacupuncture.

Chu TC, Potter DE.

J Ocul Pharmacol Ther. 2002 Aug;18(4):293-305.

PMID:
12222760
22.
23.

Muscle-specific effects of hindlimb suspension and clenbuterol in mature male rats.

Wineski LE, von Deutsch DA, Abukhalaf IK, Pitts SA, Potter DE, Paulsen DF.

Cells Tissues Organs. 2002;171(2-3):188-98.

PMID:
12097841
24.
25.

Effect of hindlimb suspension and clenbuterol treatment on polyamine levels in skeletal muscle.

Abukhalaf IK, von Deutsch DA, Wineski LE, Silvestrov NA, Abera SA, Sahlu SW, Potter DE.

Pharmacology. 2002 Jul;65(3):145-54.

PMID:
12037378
26.

Elevation of atrial natriuretic peptide levels in aqueous humor of the rabbit by kappa opioid receptor agonists.

Russell KR, Moore TT, Potter DE.

Neuropeptides. 2001 Oct-Dec;35(5-6):232-7.

PMID:
12030807
27.
28.

Distribution and muscle-sparing effects of clenbuterol in hindlimb-suspended rats.

von Deutsch DA, Abukhalaf IK, Wineski LE, Roper RR, Aboul-Enein HY, Paulsen DF, Potter DE.

Pharmacology. 2002 May;65(1):38-48.

PMID:
11901300
29.

Central imidazoline (I(1)) receptors modulate aqueous hydrodynamics.

Ogidigben MJ, Potter DE.

Curr Eye Res. 2001 May;22(5):358-66.

PMID:
11600937
30.
31.
32.
33.

Functional identification of phosphodiesterase activity in human trabecular meshwork cells.

Zhou L, Thompson WJ, Potter DE.

J Ocul Pharmacol Ther. 2000 Aug;16(4):317-22.

PMID:
10977127
34.

Beta-agonist-induced alterations in organ weights and protein content: comparison of racemic clenbuterol and its enantiomers.

von Deutsch DA, Abukhalaf IK, Wineski LE, Aboul-Enein HY, Pitts SA, Parks BA, Oster RA, Paulsen DF, Potter DE.

Chirality. 2000 Aug;12(8):637-48.

PMID:
10897101
35.

Modulation of ocular hydrodynamics and iris function by bremazocine, a kappa opioid receptor agonist.

Russell KR, Wang DR, Potter DE.

Exp Eye Res. 2000 May;70(5):675-82.

PMID:
10870526
36.

Mechanisms and sites of ocular action of 7-hydroxy-2-dipropylaminotetralin: a dopamine(3) receptor agonist.

Chu E, Chu TC, Potter DE.

J Pharmacol Exp Ther. 2000 Jun;293(3):710-6.

PMID:
10869368
37.

Comparative analytical quantitation of clenbuterol in biological matrices using GC-MS and EIA.

Abukhalaf IK, von Deutsch DA, Parks BA, Wineski L, Paulsen D, Aboul-Enein HY, Potter DE.

Biomed Chromatogr. 2000 Apr;14(2):99-105.

PMID:
10694703
38.

Potential sites of action of TNPA: a dopamine-2 receptor agonist.

Chu E, Chu TC, Potter DE.

Exp Eye Res. 1999 Dec;69(6):611-6.

PMID:
10620390
39.

8OH-DPAT-Induced ocular hypotension: sites and mechanisms of action.

Chu TC, Ogidigben MJ, Potter DE.

Exp Eye Res. 1999 Aug;69(2):227-38.

PMID:
10433858
40.

Peripheral and central effects of naphazoline on ocular hydrodynamics. Involvement of imidazoline receptors, ANP, and Gi proteins.

Ogidigben MJ, Chu TC, Potter DE.

Ann N Y Acad Sci. 1999 Jun 21;881:388-91. No abstract available.

PMID:
10415943
41.

Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells.

Zhou L, Thompson WJ, Potter DE.

Invest Ophthalmol Vis Sci. 1999 Jul;40(8):1745-52.

PMID:
10393044
42.

Intraocular pressure lowering by S-allylmercaptocysteine in rabbits.

Chu TC, Han P, Han G, Potter DE.

J Ocul Pharmacol Ther. 1999 Feb;15(1):9-17.

PMID:
10048343
43.

Lisuride acts at multiple sites to induce ocular hypotension and mydriasis.

Potter DE, Ogidigben MJ, Chu TC.

Pharmacology. 1998 Nov;57(5):249-60.

PMID:
9742290
44.

Potential mechanisms of moxonidine-induced ocular hypotension: role of norepinephrine.

Chu TC, Socci RR, Ogidigben MJ, Potter DE.

J Ocul Pharmacol Ther. 1997 Dec;13(6):489-96.

PMID:
9436152
45.
46.

Oxymetazoline: potential mechanisms of inhibitory effects on aqueous humor dynamics.

Chu TC, Ogidigben MJ, Potter DE.

Pharmacology. 1996 Oct;53(4):259-70.

PMID:
8958565
47.

Elevation of intracellular Ca2+ concentration in rabbit nonpigmented ciliary epithelial cells by allicin.

Chu TC, Burch JL, de Paula Brotto MA, Creazzo TL, Han J, Han GY, Potter DE.

Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1996 Sep;115(1):89-94.

PMID:
8983172
48.

Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors.

Chu TC, Wong W, Gluchowski C, Hughes BW, Potter DE.

Curr Eye Res. 1996 Sep;15(9):943-50.

PMID:
8921215
49.

The Medical Expenditure Panel Survey: a national health information resource.

Cohen JW, Monheit AC, Beauregard KM, Cohen SB, Lefkowitz DC, Potter DE, Sommers JP, Taylor AK, Arnett RH 3rd.

Inquiry. 1996-1997 Winter;33(4):373-89.

PMID:
9031653
50.

Ocular action of an opioid peptide, DPDPE.

Wang D, Potter DE.

J Ocul Pharmacol Ther. 1996 Summer;12(2):131-9.

PMID:
8773929

Supplemental Content

Loading ...
Support Center